This is to inform you that the Board of Directors of the Company at their meetings held on 5th February 2019 approved the following: The Company has acquired all the shares of Suven Pharmaceuticals Limited ('SPL'), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals Limited has become a wholly owned subsidiary of the Company. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that on January 6, 2020 the Hon''ble National Company Law Tribunal, Bench at Hyderabad ('NCLT') has passed order allowing the Company Petition filed for sanction of the Composite Scheme of Arrangement ('Scheme') under Sections 230 to 232 read with Section 66 and other applicable provisions of the Companies Act, 2013 amongst Suven Life Sciences Limited ('Demerged Company') and Suven Pharmaceuticals Limited ('Resulting Company') and their respective Shareholders and Creditors (As Per BSE Announcement dated on 07/01/2020) Trading Members of the Exchange are hereby informed that, pursuant to the Scheme of Arrangement (for Demerger) approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT), Suven Life Sciences Ltd. has fixed the Record Date for the purpose of determining entitlement of the shareholders of the Company, as per details given below: COMPANY NAME CODE Suven Life Sciences Ltd. (530239) RECORD DATE 22/01/2020 PURPOSE As per Scheme of Arrangement sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT), between, Suven Life Sciences Ltd. (Transferor Company) and Suven Pharmaceuticals Limited (Transferee Company) and Their Respective Shareholders and Creditors: - Upon the coming into effect of the aforesaid Scheme and in consideration of the transfer of the Contract Research & Manufacturing Services of Suven Life Sciences Ltd. into Suven Pharmaceuticals Limited; Suven Pharmaceuticals Limited shall issue and allot Equity Shares to the shareholders of Suven Pharmaceuticals Limited in the following proportion: '1 fully paid up equity share of Rs.1/- each fully paid up of Suven Pharmaceuticals Limited shall be issued and allotted for every 1 (One) fully paid up equity share of Rs. 1/- each fully paid up held in Suven Life Sciences Ltd.' EX-ENTITLEMENT FROM DATE & SETT. NO. 21/01/2020 DR-200/2019-2020 Note: Pursuant to SEBI Circular No. SEBI/Cir/ISD/1/2010 dated November 2, 2010, Trading members are hereby informed that the trading in the equity shares of the aforesaid company shall be transferred from A' group to T' group w.e.f. January 21, 2020 and pursuant to SEBI Circular No. CIR/MRD/DP/01/2012 dated January 20, 2012; the aforesaid scrip shall be a part of Call Auction in Pre-open Session on January 21, 2020. Subject to compliance with requisite formalities, the shares of Resulting company i.e. Suven Pharmaceuticals Limited will be listed on BSE Limited. (As Per BSE Notice Dated on 15.01.2020) Please find enclosed herewith communication being issued for general guidance of shareholders of the Company in relation to apportionment of the cost of acquisition of shares of Suven Life Sciences Limited and Suven Pharmaceuticals Limited as per the provisions of the Income Tax Act, 1961. (As per BSE Announcement dated on 21/01/2020) With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Suven Life Sciences Ltd has submitted to BSE a copy of Clarification is enclosed. (As Per BSE Announcement dated on 04/02/2020)